With semaglutide’s patent expiry, Indian drugmakers are gearing up to launch affordable alternatives, significantly expanding access
Entry of multiple players could reduce prices by 50–70 per cent, making weight-loss drugs accessible to a wider population
Rising obesity and diabetes rates are driving demand, creating a large and fast-expanding domestic market for such therapies
Weak regulatory oversight and subcontracted production raise risks around safety, consistency, and the spread of counterfeit drugs
Easy access and self-medication, often without proper supervision, could undermine treatment outcomes and patient safety
Robust regulation and medical supervision will be key to ensuring safety, building trust, and enabling global market entry